Strategies for Addressing Resistance and Off-Target Toxicity in Antibody-Drug ConjugatesFebruary 24, 2026
FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized TherapiesFebruary 24, 2026
DNA & Genetics What the FDA’s Priority Voucher Decision Means for Psychedelic Drug DevelopmentBy adminFebruary 24, 20260 Credit: Alfred Pasieka/Science Photo Library/Getty Images The FDA Commissioner’s National Priority Review Voucher (CNPV) Pilot Program was created to accelerate…
